Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002 AM1)

Inclusion Criteria:

- Male or female of non-child bearing potential

- Body Mass Index ≤40 kg/m^2

- Diagnosis of Type 2 Diabetes (T2DM) and is either drug naive or is being treated with
metformin only

- In good health except for T2DM

- Willing to follow a standard diet

- Nonsmoker and/or no use of nicotine or nicotine-containing products for 6 months

Exclusion Criteria:

- Mentally or legally incapacitated

- History of stroke, chronic seizures, or major neurological disorder

- History of clinically significant endocrine (except T2DM), gastrointestinal,
cardiovascular, hematological, hepatic, immunological, renal, respiratory, or
genitourinary abnormalities or diseases

- History of neoplastic or myeloproliferative diseases

- Has clinical unstable or rapidly progressing diabetic retinopathy, neuropathy, and/or
frequent nausea, bloating or vomiting, severe gastroesophageal reflux or early
satiety

- Has a history of Type 1 Diabetes and/or history of ketoacidosis

- Use of any lipid-lowering therapies in the past 3 months

- Non-permitted medication for a co-morbid condition

- Excessive alcohol or caffeine use

- Participation in another investigational study within 4 weeks prior to this study

- A history of significant multiple and/or severe allergies or anaphylactic reactions

- Regular user of any illicit drugs or history of alcohol abuse within 6 months